Business Wire

VÄRDE-PARTNERS

Share
Värde Funds $155 Million for Two Office Developments in Hyderabad, India

Värde Partners, a leading global alternative investment firm, today announced it has provided senior construction financing on two pre-leased office assets in the Gachibowli Financial District of Hyderabad, India.

The $155 million facility will be used to refinance and fund to completion over 2.5 million square feet across the two Grade A developments owned by Phoenix Group. To date, over 1.5 million square feet has been pre-let to two multi-national companies, reflecting the quality and location of the assets. Construction of both projects is well-advanced, with sub-structure development complete and super-structure phases underway.

Hyderabad is a recognized global tech hub, with the city’s financial district home to a large number of multi-national tech, financial services and professional services companies. Hyderabad is one of the fastest growing metropolitan cities in India and one of the strongest markets in the country for office absorption.

Värde believes that India’s real estate market is experiencing a significant imbalance in the supply and demand of capital, leading to many businesses with robust balance sheets seeking alternative sources of capital.

“We see significant opportunity across the Indian office market for both the financing and purchase of assets, in a market that offers potential strong cash-flow visibility, multinational tenants and strong absorption,” said Tim Mooney, Partner and Global Head of Real Estate at Värde Partners. “India is a dramatic example, but emblematic of what we're seeing across the Asia Pacific region, and across the globe. We believe that a real estate cycle is upon us and while not nearly as pronounced as the cycle brought on by the global financial crisis, the opportunity set is significant and growing.”

About Värde Partners

Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested $75 billion since inception and manages more than $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com .

About Phoenix Group

Phoenix Group, a Hyderabad focused group, is one of the leading Grade A commercial office space developers who have successfully developed more than 12 million SF of mixed-use developments. The group has a healthy pipeline of SEZ and Office space developments and has been at the forefront of developing and leasing quality office space in Hyderabad. Investment by Ascendas India Trust in the SEZ development projects and Lake Shore India Advisory in the mall projects are some of the notable strategic investments attracted by the group in the past (https://www.phoenixindia.net/about.html ).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 09:00:00 CET | Press release

MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in

NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 08:44:00 CET | Press release

NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c

Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 202629.10.2025 08:00:00 CET | Press release

Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023 Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe.

Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 08:00:00 CET | Press release

Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performanc

Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care29.10.2025 07:28:00 CET | Press release

Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/ Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care. Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance. These developments come amid China’s ongoing demographic transformation. By

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye